CIK 0001766140
- Emerging growth company
Unicycive Therapeutics, Inc.
Sign in to watch- Ticker
- UNCY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813638692
- Phone
- +1 650-384-0642
- Business address
- 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
- Former names
- Unicycive Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-25 | Aggarwal Gaurav Director | Conversion | +652,900 | 1,789,915 | ||
| 2025-08-25 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −3,199.21 | $1,000.00 | $3.2M | 0 |
| 2025-07-28 | Aggarwal Gaurav Director | Grant or award · Stock Options | +21,200 | 39,200 | ||
| 2025-02-18 | Aggarwal Gaurav Director | Conversion | +1,400,000 | 11,370,152 | ||
| 2025-02-18 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −686 | $1,000.00 | $686K | 3,119.21 |
| 2024-10-09 | Aggarwal Gaurav Director | Conversion | +5,500,000 | 9,970,152 | ||
| 2024-10-09 | Aggarwal Gaurav Director | Returned to the company · Series A-2 Prime Preferred Stock | −2,695 | $1,000.00 | $2.7M | 3,885.21 |
| 2023-09-05 | Aggarwal Gaurav Director | Grant or award · Stock Options | +180,000 | 180,000 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion | +3,470,152 | 3,470,152 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Series A-1 Preferred Stock | −8,077 | $1,000.00 | $8.1M | 0 |
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Series A-2 Preferred Stock | +13,429,000 | 13,429,000 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche A Warrants (right to buy) | +12,802,388 | 12,802,388 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche B Warrants (right to buy) | +11,638,534 | 11,638,534 | ||
| 2023-07-11 | Aggarwal Gaurav Director | Conversion · Tranche C Warrants (right to buy) | +18,621,655 | 18,621,655 | ||
| 2023-03-08 | Aggarwal Gaurav Director | Grant or award · Series A-1 Convertible Preferred Stock | +8,077 | $1,000.00 | $8.1M | 8,077 |
Page 1 of 1 · 15 trades